Key result
A 1 standard deviation increase in resting heart rate measured by a wearable device was significantly associated with an increased risk of thyrotoxicosis (OR 3.840; 95% CI 2.113-6.978; P<0.001).
Why the study?
Does resting heart rate measured by a wearable activity tracker correlate with thyroid function in patients with thyrotoxicosis?
Observational (n=40)
Does resting heart rate measured by a wearable activity tracker correlate with thyroid function in patients with thyrotoxicosis?
Resting heart rate measured by a wearable device correlates well with thyroid function and may be a clinically feasible parameter for managing thyrotoxicosis.
Wearable heart rate monitoring may flag thyrotoxicosis risk; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND Symptoms and signs of thyrotoxicosis are nonspecific and assessing its clinical status is difficult with conventional physical examinations and history taking. Increased heart rate (HR) is one of the easiest signs to quantify this, and current wearable devices can monitor HR. OBJECTIVE We assessed the association between thyroid function and resting HR measured by a wearable activity tracker (WD-rHR) and evaluated the clinical feasibility of using this method in patients with thyrotoxicosis. METHODS Thirty patients with thyrotoxicosis and 10 controls were included in the study. Participants were instructed to use the wearable activity tracker during the study period so that activity and HR data could be collected. The primary study outcomes were verification of changes in WD-rHR during thyrotoxicosis treatment and associations between WD-rHR and thyroid function. Linear and logistic model generalized estimating equation analyses were performed and the results were compared to conventionally obtained resting HR during clinic visits (on-site resting HR) and the Hyperthyroidism Symptom Scale. RESULTS WD-rHR was higher in thyrotoxic patients than in the control groups and decreased in association with improvement of thyrotoxicosis. A one standard deviation–increase of WD-rHR of about 11 beats per minute (bpm) was associated with the increase of serum free T4 levels (beta=.492, 95% CI 0.367-0.616, P<.001) and thyrotoxicosis risk (odds ratio [OR] 3.840, 95% CI 2.113-6.978, P<.001). Although the Hyperthyroidism Symptom Scale showed similar results with WD-rHR, a 1 SD-increase of on-site rHR (about 16 beats per minute) showed a relatively lower beta and OR (beta=.396, 95% CI 0.204-0.588, P<.001; OR 2.114, 95% CI 1.365-3.273, P<.001) compared with WD-rHR. CONCLUSIONS Heart rate data measured by a wearable device showed reasonable predictability of thyroid function. This simple, easy-to-measure parameter is clinically feasible and has the potential to manage thyroid dysfunction. CLINICALTRIAL ClinicalTrials.gov NCT03009357; https://clinicaltrials.gov/ct2/show/NCT03009357 (Archived by WebCite at http://www.webcitation.org/70h55Llyg)
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted an observational in Thyrotoxicosis (n=40). Resting heart rate measured by a wearable activity tracker (WD-rHR) vs. Controls / On-site resting HR was evaluated on Thyrotoxicosis risk associated with a 1 SD-increase in WD-rHR (OR 3.840, 95% CI 2.113-6.978, p=<.001). A 1 standard deviation increase in resting heart rate measured by a wearable device was significantly associated with an increased risk of thyrotoxicosis (OR 3.840; 95% CI 2.113-6.978; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: